News

Astellas Receives Health Canada Approval for VYLOY ® (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer VYLOY is the first and only therapy approved in Canada to target claudin 18.2, a biomarker positively expressed by 38% of patients with advanced gastric cancer 1 , 2 Treatment with VYLOY shown to significantly extend both progression-free...

New treatment option helps fill unmet need for women experiencing hot flashes and night sweats associated with menopause MARKHAM, ON, December 3, 2024 – Today, Astellas Pharma Canada, Inc. is proud to announce the Health Canada approval of VEOZAH ® (fezolinetant film-coated tablets), the first and only non-hormonal treatment indicated for the treatment of moderate to severe vasomotor symptoms (VMS...

HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine therapy Canadian team has dosed first patient in HIGHLIGHT 1™ Phase 3 study Markham, ON, August 27, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), the parent company of...

XTANDI® (enzalutamide) Receives Health Canada Approval as the First and Only Treatment for High-Risk Patients with Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) MARKHAM, ON, January 30, 2024 – Today, Astellas Pharma Canada, Inc. announced that Health Canada has approved a supplemental New Drug Application for XTANDI® (enzalutamide) in a new prostate cancer treatment setting. With...

Astellas Pharma Canada, Inc. Recognized Again as a Best Workplace™ in Ontario MARKHAM, ON, November 17, 2022 – Astellas Pharma Canada, Inc. is proud to announce that our organization has been named on the 2022 list of Best Workplaces™ in Ontario by Great Place to Work ® for the third year in a row. This recognition comes in addition to being listed for the seventh consecutive year as a Best...